Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR Pathway

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 40-45

  Srivastava, Vikas Kumar ^b   Gara, Rishi Kumar ^a   Bhatt, M L B ^b   Sahu, D P ^a   Mishra, Durga Prasad ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Apoptosis; Centchroman; Head and neck cancer; PI3K mTOR; STAT3

Indexed keywords

CENTCHROMAN; DNA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; ENZYME INHIBITION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CENTCHROMAN; DNA DAMAGE; ESTROGEN ANTAGONISTS; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 78650885823     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.049     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
2. Matta A., Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol. 2009, 1:6.
3. Leeman R.J., Lui V.W., Grandis J.R. STAT3 as a therapeutic target in head and neck cancer. Expert Opin. Biol. Ther. 2006, 6:231-241.
4. Leeman-Neill R.J., Wheeler S.E., Singh S.V., Thomas S.M., Seethala R.R., Neill D.B., Panahandeh M.C., Hahm E.R., Joyce S.C., Sen M., Cai Q., Freilino M.L., Li C., Johnson D.E., Grandis J.R. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009, 30:1848-1856.
5. Wheeler S.E., Suzuki S., Thomas S.M., Sen M., Leeman-Neill R.J., Chiosea S.I., Kuan C.T., Bigner D.D., Gooding W.E., Lai S.Y., Grandis J.R. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29:5135-5145.
6. Bussink J., van der Kogel A.J., Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008, 9:288-296.
7. Moral M., Paramio J.M. Akt pathway as a target for therapeutic intervention in HNSCC. Histol. Histopathol. 2008, 23:1269-1278.
8. Vivanco I., Sawyers G.L. The phosphatidylinositol 3 kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
9. Kamboj V.P., Setty B.S., Chandra H., Roy S.K., Kar A.B. Biological profile of Centchroman - a new post-coital contraceptive. Indian J. Exp. Biol. 1977, 15:1144-1150.
10. Misra N.C., Nigam P.K., Gupta R., Agarwal A.K., Kamboj V.P. Centchroman - a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study. Int. J. Cancer 1989, 43:781-783.
11. Nigam M., Ranjan V., Srivastava S., Sharma R., Balapure A.K. Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells. Life Sci. 2008, 82:577-590.
12. Singh M.M. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med. Res. Rev. 2001, 21:302-347.
13. Kumar S., Lavin M.F. The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ. 1996, 3:255-267.
14. Kathrin S.Z., Olof I.H., Anne S., Teet V., Shaun P.J., Julian D., Anders T., Staffan J. PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading. Cell. Signalling 2010, 22:1838-1848.
15. Shile H., Peter J.H. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003, 3:371-377.
16. Koul N., Sharma V., Dixit D., Ghosh S., Sen E. Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells. BMC Cancer 2010, 10:328.
17. Zhang C., Yang N., Yang C.H., Ding H.S., Luo C., Zhang Y., Wu M.J., Zhang X.W., Shen X., Jiang H.L., Meng L.H., Ding J. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One 2009, 4:e4881.
18. Paternot S., Roger P.P. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer Res. 2009, 69:4577-4581.
19. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
20. Furuta T., Takemura H., Liao Z.Y., Aune G.J., Redon C., Sedelnikova O.A., Pilch D.R., Rogakou E.P., Celeste A., Chen H.T., Nussenzweig A., Aladjem M.I., Bonner W.M., Pommier Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 2003, 278:20303-20312.
21. Tavassoli M., Soltaninia J., Rudnicka J., Mashanyare D., Johnson N., Gaken J. Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-beta1. Carcinogenesis 2002, 23:1569-1575.
22. Teixeira C., Stang S.L., Zheng Y., Beswick N.S., Stone J.C. Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood 2003, 102:1414-1420.
23. Oka M., Sumita N., Sakaguchi M., Iwasaki T., Bito T., Kageshita T., Sato K., Fukami Y., Nishigori C. 12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s). J. Biol. Chem. 2009, 284:30416-30423.
24. Quintanilla-Martinez L., Kremer M., Specht K., Calzada-Wack J., Nathrath M., Schaich R., Hofler H., Fend F. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am. J. Pathol. 2003, 162:1449-1461.
25. Coqueret O., Gascan H. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J. Biol. Chem. 2000, 275:18794-18800.
26. Covell D.G., Wallqvist A., Huang R., Thanki N., Rabow A.A., Lu X.J. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 2005, 59:403-433.